Jennifer S. Buell/LinkedIn
Apr 4, 2025, 09:40
Jennifer Buell: BOTENSILIMAB is changing treatment landscape in MSS colon cancer
Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics and Executive Council at Agenus, shared a post on X:
“MSS colon cancer has long resisted immunotherapy.;
BOTENSILIMAB is changing this:
- 29% pCR in (UNICORN).
- 100% RFS at 18.2 mos (NEST).
- 19% ORR in r/r mCRC.
- 71% ORR w/ chemo + targeted Tx in 1L CRC.”
More updates on Botensilimab.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54
Sep 2, 2025, 16:41
Sep 2, 2025, 16:27